StreetInsider.com News Articles

Awakn Life Sciences Announces Credit Facility

Wed, 18 Dec 2024 08:30:00 -0400

Toronto, Ontario--(Newsfile Corp. - December 18, 2024) - Awakn Life Sciences Corp. (CSE: AWKN) (OTCQB: AWKNF) (FSE: 954) ("Awakn" or the "Company") a clinical-stage biotechnology company developing therapeutics for substance use and mental health disorders, is pleased to announce that it has obtained an unsecured credit facility of up to US$535,000 (the "Facility") from an arm's length creditor of the Company, which can be drawn upon by the Company in multiple advances, and which is evidenced by a grid promissory note issued by the Company (the "Grid Note"). The principal drawn under the Facility shall become due and payable on

Awakn Life Sciences Announces Credit Facility

Wed, 18 Dec 2024 08:30:00 -0400

Awakn Life Sciences Enters into Binding Letter of Intent for Acquisition of Awakn by Graft Polymer (UK) Plc

Mon, 16 Dec 2024 08:30:00 -0400

Toronto, Ontario--(Newsfile Corp. - December 16, 2024) - Awakn Life Sciences Corp. (CSE: AWKN) (OTCQB: AWKNF) (FSE: 954) ("Awakn" or the "Company") a clinical-stage biotechnology company developing therapeutics for substance use and mental health disorders, is pleased to announce that it has entered into a binding letter of intent (the "LOI") dated December 15, 2024, with Graft Polymer (UK) PLC ("Graft"), pursuant to which Graft would acquire all of the issued and outstanding common shares (the "Common Shares") in the capital of the Company, all outstanding restricted share units (the "RSUs") in the capital of the Company, and all outstanding deferred

Awakn Life Sciences Enters into Binding Letter of Intent for Acquisition of Awakn by Graft Polymer (UK) Plc

Mon, 16 Dec 2024 08:30:00 -0400

Awakn Announces Promising Results from Aminoindane New Chemical Entity Pre-Clinical Program

Tue, 10 Dec 2024 17:30:00 -0400

Toronto, Ontario--(Newsfile Corp. - December 10, 2024) - Awakn Life Sciences Corp. (CSE: AWKN) (OTCQB: AWKNF) (FSE: 954) ("Awakn" or the "Company"), a clinical-stage biotechnology company developing therapeutics for substance use and mental health disorders, today announces initial results from a preclinical study of its co-lead aminoindane series (AW21003) conducted by the University of Nottingham. This program focuses on new therapeutic options for trauma-related mental health disorders, particularly Post-Traumatic Stress Disorder (PTSD).

Aminoindanes are a class of compounds being explored in pre-clinical models by Awakn for their ability to promote pro-social behavior with a potentially improved safety profile compared to existing

Awakn Announces Promising Results from Aminoindane New Chemical Entity Pre-Clinical Program

Tue, 10 Dec 2024 17:30:00 -0400

Aminoindanes are a class of compounds being explored in pre-clinical models by Awakn for their ability to promote pro-social behavior with a potentially improved safety profile compared to existing

Awakn Announces Opening of Four Additional AWKN-001 Phase 3 Trial Sites

Tue, 22 Oct 2024 07:30:00 -0400

Toronto, Ontario--(Newsfile Corp. - October 22, 2024) - Awakn Life Sciences Corp. (CSE: AWKN) (OTCQB: AWKNF) (FSE: 954) ("Awakn" or the "Company"), a clinical-stage biotechnology company developing therapeutics for substance use and mental health disorders, announces the opening of four additional clinical trial sites: University Hospitals Sussex NHS Foundation Trust; South London and Maudsley NHS Foundation Trust; Greater Manchester Mental Health NHS Foundation Trust; and University Hospitals Plymouth NHS Trust. This brings the total active trial sites to 7 in the landmark 'MORE-KARE' Phase 3 trial of AWKN-001 for severe AUD.

AWKN-001 is an investigational, novel medication-assisted treatment for severe AUD,

Awakn Announces Opening of Four Additional AWKN-001 Phase 3 Trial Sites

Tue, 22 Oct 2024 07:30:00 -0400

AWKN-001 is an investigational, novel medication-assisted treatment for severe AUD,

Awakn Partners with the University of Nottingham for in Vivo Testing of Aminoindane New Chemical Entity (NCE) Pre-Clinical Program

Tue, 15 Oct 2024 07:30:00 -0400

Toronto, Ontario--(Newsfile Corp. - October 15, 2024) - Awakn Life Sciences Corp. (CSE: AWKN) (OTCQB: AWKNF) (FSE: 954) ("Awakn" or the "Company"), a clinical-stage biotechnology company developing therapeutics for substance use and mental health disorders, announces a new research partnership with the University of Nottingham, UK. This collaboration focuses on evaluating Awakn's co-lead aminoindane series and its potential to enhance social cognition and pro-social behaviors.

The study will be led by Dr. Madeleine King, Assistant Professor in the School of Life Sciences in the Faculty of Medicine & Health Sciences at the University of Nottingham, a globally recognized institution for its

Awakn Partners with the University of Nottingham for in Vivo Testing of Aminoindane New Chemical Entity (NCE) Pre-Clinical Program

Tue, 15 Oct 2024 07:30:00 -0400

Awakn Selects Eurofins Discovery for Pharmacology Testing in New Chemical Entity (NCE) Pre-Clinical Program

Fri, 04 Oct 2024 07:30:00 -0400

Toronto, Ontario--(Newsfile Corp. - October 4, 2024) - Awakn Life Sciences Corp. (CSE: AWKN) (OTCQB: AWKNF) (FSE: 954) ("Awakn" or the "Company"), a clinical-stage biotechnology company focused on developing therapeutics for substance use and mental health disorders, with a near-term focus on Alcohol Use Disorder ("AUD"), today announced the selection of Eurofins Discovery to conduct initial pharmacology testing for its co-lead aminoindane series as part of Awakn's New Chemical Entity (NCE) pre-clinical program.

Eurofins Discovery, an industry-leading provider of products and services for drug discovery research, will play a pivotal role in advancing Awakn's pre-clinical research efforts. This testing phase marks

Awakn Selects Eurofins Discovery for Pharmacology Testing in New Chemical Entity (NCE) Pre-Clinical Program

Fri, 04 Oct 2024 07:30:00 -0400

Awakn Life Sciences Announces Upsizing and Closing of Tranche of Private Placement Financing

Wed, 18 Sep 2024 07:30:00 -0400

Toronto, Ontario--(Newsfile Corp. - September 18, 2024) - Awakn Life Sciences Corp. (CSE: AWKN) (OTCQB: AWKNF) (FSE: 954) ("Awakn" or the "Company") a clinical-stage biotechnology company developing therapeutics for substance use and mental health disorders, with a near-term focus on Alcohol Use Disorder ("AUD"), is pleased to announce that, further to its press releases dated April 3, 2024, April 17, 2024, June 4, 2024 and July 31, 2024, it has determined to increase the size of its previously announced non-brokered private placement financing (the "Offering") from up to $1,000,000 to up to $2,000,000. Additionally, Awakn is pleased to announce the

Awakn Life Sciences Announces Upsizing and Closing of Tranche of Private Placement Financing

Wed, 18 Sep 2024 07:30:00 -0400

Awakn Announces Key Progress in Its Aminoindane Pre-Clinical Program

Wed, 28 Aug 2024 07:30:00 -0400

Toronto, Ontario--(Newsfile Corp. - August 28, 2024) - Awakn Life Sciences Corp. (CSE: AWKN) (OTCQB: AWKNF), a clinical-stage biotechnology company developing therapeutics for substance use and mental health disorders, is pleased to provide an update on the progress of its pre-clinical program being executed as part of a commercial collaboration with Graft Polymer (UK) Plc (LSE: GPL) ("Graft Polymer"), an innovative healthcare industry services company.

The collaboration focuses on developing a new class of therapeutics for the potential treatment of trauma-related mental health disorders, such as Post-Traumatic Stress Disorder ("PTSD"), which affects approximately 13 million adults in the U.S. and 20

Awakn Announces Key Progress in Its Aminoindane Pre-Clinical Program

Wed, 28 Aug 2024 07:30:00 -0400

Awakn Announces First Patient Screened in Phase 3 Clinical Trial of AWKN-001 for Severe Alcohol Use Disorder

Fri, 09 Aug 2024 07:30:00 -0400

Toronto, Ontario--(Newsfile Corp. - August 9, 2024) - Awakn Life Sciences Corp. (CSE: AWKN) (OTCQB: AWKNF) (FSE: 954) ("Awakn" or the "Company"), a clinical-stage biotechnology company developing therapeutics for substance use and mental health disorders, with a near-term focus on Alcohol Use Disorder ("AUD"), announces that the first patient has been screened in the landmark 'MORE-KARE' Phase 3 trial of AWKN-001 for severe AUD.

AWKN-001 is an investigational, novel medication-assisted treatment for severe AUD, consisting of an N-methyl-D-aspartate receptor-modulating drug (ketamine) delivered intravenously (IV) in combination with manualized psycho-social support for severe AUD.

The MORE-KARE study, or the Multicentre Investigation

Awakn Announces First Patient Screened in Phase 3 Clinical Trial of AWKN-001 for Severe Alcohol Use Disorder

Fri, 09 Aug 2024 07:30:00 -0400

The MORE-KARE study, or the Multicentre Investigation

Awakn Life Sciences Announces Closing of Tranche of Private Placement and Warrant Extension

Wed, 31 Jul 2024 07:30:00 -0400

Toronto, Ontario--(Newsfile Corp. - July 31, 2024) - Awakn Life Sciences Corp. (CSE: AWKN) (OTCQB: AWKNF) (FSE: 954) ("Awakn" or the "Company") a clinical-stage biotechnology company developing therapeutics for substance use and mental health disorders, with a near-term focus on Alcohol Use Disorder ("AUD"), is pleased to announce that, further to its press releases dated April 3, 2024, April 17, 2024, and June 4, 2024 it has closed a third tranche of its previously announced non-brokered private placement (the "Offering") through the issuance of an additional 428,571 units (the "Units") at a price of $0.46 per Unit for additional gross

Awakn Life Sciences Announces Closing of Tranche of Private Placement and Warrant Extension

Wed, 31 Jul 2024 07:30:00 -0400

Awakn Life Sciences Provides Update on Aminoindane New Chemical Entity Patent Portfolio

Mon, 22 Jul 2024 17:00:00 -0400

Toronto, Ontario--(Newsfile Corp. - July 22, 2024) - Awakn Life Sciences Corp. (CSE: AWKN) (OTCQB: AWKNF) (FSE: 954) ("Awakn" or the "Company"), a clinical-stage biotechnology company developing therapeutics for substance use and mental health disorders, with a near-term focus on Alcohol Use Disorder ("AUD"), is pleased to provide details of the status of the intellectual property ("IP") portfolio for its aminoindane new chemical entity ("NCE") series program (the "Aminoindane NCEs") being developed in commercial collaboration with Graft Polymer (UK) Plc (LSE: GPL) ("Graft"). Details of the commercial collaboration agreement with Graft were announced on July 18, 2024.

The Aminoindane NCEs

The Aminoindane

Awakn Life Sciences Provides Update on Aminoindane New Chemical Entity Patent Portfolio

Mon, 22 Jul 2024 17:00:00 -0400

The Aminoindane NCEs

The Aminoindane

Awakn Life Sciences Announces Collaboration Agreement with Graft Polymer (UK) PLC

Thu, 18 Jul 2024 07:30:00 -0400

Toronto, Ontario--(Newsfile Corp. - July 18, 2024) - Awakn Life Sciences Corp. (CSE: AWKN) (OTCQB: AWKNF) (FSE: 954) ("Awakn" or the "Company"), a clinical-stage biotechnology company developing therapeutics for substance use and mental health disorders, with a near-term focus on Alcohol Use Disorder ("AUD"), is pleased to announce that it has entered into a commercial collaboration agreement dated July 17, 2024 (the "Collaboration Agreement") with Graft Polymer (UK) Plc (LON: GPL) ("Graft"), an innovative biopolymer drug delivery systems development company. The collaboration is focused on developing Awakn's novel aminoindane new chemical entity series programme (the "Aminoindane NCEs") which have potential

Awakn Life Sciences Announces Collaboration Agreement with Graft Polymer (UK) PLC

Thu, 18 Jul 2024 07:30:00 -0400